Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries

Journal of Thrombosis and Thrombolysis

Volumn 26, Issue 2, 2008, Pages 125-131

  Happe, Laura Elizabeth ^a   Farrelly, Eileen Marie ^a   Stanford, Richard H ^b   Sarnes, Matt William ^a  

^a XCENDA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Anticoagulant; Fondaparinux; Healthcare cost; Heparin; Incidence; Orthopaedic surgery; Outcomes; Thrombocytopenia; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG CHOICE; FEMALE; HEALTH CARE COST; HIP FRACTURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; COHORT STUDIES; DALTEPARIN; ENOXAPARIN; FEMALE; HEALTH CARE COSTS; HEPARIN; HUMANS; INCIDENCE; INJECTIONS; LENGTH OF STAY; MALE; ODDS RATIO; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 56049127385     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0170-1     Document Type: Article

References (34)

1. Warkentin TE, Roberts RS, Hirsh J, Kelton JG (2003). An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 163:2518-2524
2. Merck Manual Online Medical Library (2006) Thrombocytopenia. Available from http://www.merck.com/mmhe/sec14/ch173/ch173d.html. Accessed August 21, 2006
3. Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A (2002) The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 116:887-891
4. Kelton JG (1999) The clinical management of heparin-induced thrombocytopenia. Semin Hematol 36(suppl 1):17-21
5. King DJ, Kelton JG (1984) Heparin-associated thrombocytopenia. Ann Intern Med 100:535-540
6. Spinler SA, Dager W (2003) Overview of heparin-induced thrombocytopenia. Am J Health Syst Pharm 60(Suppl 5):S5-11
7. Visentin GP (1999) Heparin-induced thrombocytopenia: Molecular pathogenesis. Semin Thrombos Haemostas 82:448-456
8. Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(Suppl 3):311-337
9. Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood 106:2710-2715
10. Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):S338-400
11. Efird LE, Kockler DR (2006) Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 40:1383-1387
12. Boon DM, Michels JJ, Stibbe J, van Vliet HH, Kappers-Klune MC (1994) Heparin-induced thrombocytopenia and antithrombotic therapy (letter). Lancet 344:1296
13. Greinacher A, Eichler P, Lubenow N, Kwasng H, Luz M (2000) Heparin induced thrombocytopenia with thromboembolic complications: Meta analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846-851
14. Warkentin TE (2005) New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 127(2 suppl):35S-45S
15. Girolami B, Prandoni P, Stefani PM et al (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study. Blood 101:2955-2959
16. Warkentin TE, Greinacher A (2001) Clinical picture of heparin-induced thrombocytopenia. In: Heparin-induced thrombocytopenia, 2nd edn. Marcel Dekker Inc., New York, pp 43-86
17. Hirsh J, Heddle N, Kelton JG (2004) Treatment of heparin-induced thrombocytopenia. Arch Intern Med 164:361-369
18. O'Brien JA, Caro JJ (2002) Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 20:603-615
19. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI (2006) Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 26(10):1438-1445
20. Bussey H, Francis JL, the Heparin Consensus Group (2004) Heparin overview and issues. Pharmacotherapy 24(8 pt 2):S103-107
21. Savi P, Chong BH, Greinacher A et al (2005) Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin. Blood 105:139-144
22. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM (2005) Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 353:349-361
23. Ouriel K, Kaul AF, Leonard MC (2004) Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg 40:971-977
24. Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD (2004) Resource use and cost of care for patients hospitalized with community acquired pneumonia: Impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics 22:751-757
25. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619
26. Bernardini J, Callen S, Fried L, Piraino B (2004) Inter-rater reliability and annual rescoring of the Charlson comorbidity index. Adv Perit Dial 20:125-127
27. Roos LL, Sharp SM, Cohen MM (1991) Comparing clinical information with claims data: Some similarities and differences. J Clin Epidemiol 44(9):881-888
28. Roos LL, Sharp SM, Cohen MM, Wajda A (1989) Risk adjustment in claims-based research: The search for efficient approaches. J Clin Epidemiol 42:1193-1206
29. O'Connor GT, Plume SK, Olmstead EM et al (1991) A regional prospective study of in-hospital mortality associated with coronary artery bypass grafting. The Northern New England Cardiovascular Disease Study Group. JAMA 266:803-809
30. Warkentin TE, Levine MN, Hirsch J et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335
31. Warkentin TE, Kelton JG (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507
32. Frame JN (2005) The heparin-induced thrombocytopenia task force model: implementing quality improvement and economic outcome initiatives. Semin Hematol 42(Suppl 3):S28-35
33. Kang SK, Wordell CJ, Senholzi C, Chambers L (2004) Cost of enoxaparin for prevention and/or treatment of thromboembolic events vs. the cost of treating heparin-induced thrombocytopenia (HIT): A cost-benefit analysis [Abstract]. Presented at ASHP 39th midyear clinical meeting and exhibits, December 5-9, 2004, Orlando, FL. Available from http://ashp.omnibooksonline.com/2004/. Abstract MCS-18. Accessed January 19, 2007
34. Elting LS, Cantor SB, Martin CG et al (2003) Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97:1541-1550